Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of RT001 Topical Gel for Primary Axillary Hyperhidrosis
NCT02565732Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daxibotulinumtoxinA in primary axillary hyperhidrosis (PAH) (3 arms), sponsored by Revance Therapeutics. Primary endpoints: Hyperhidrosis Disease Severity Scale at 4 weeks and Gravimetric Sweat Production at 4 weeks. Started Sep 2015; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT02565732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565732.